Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.

This case series found that paclitaxel and nab-paclitaxel may be safe and effective chemotherapy options for hemodialysis patients with unresectable advanced or recurrent gastric cancer.

This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.